The administration of letrozole at doses of 7.5 mg reduced the incidence of moderate and severe OHSS in high-risk patients by dose-dependently lowering estradiol and VEGF levels [51]. This evidence concerns the gene VEGFA and ovarian hyperstimulation syndrome.